Revolution Medicines Inc (RVMD)

Nov 19, 2024

Victory Capital Management Inc. Sells 104,851 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Nov 19, 2024

Nov 16, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $61.00 Average Price Target from Brokerages - Defense World

Nov 16, 2024

Nov 15, 2024

Revolution Medicines executive sells shares worth $977,508 By Investing.com - Investing.com Australia

Nov 15, 2024

Nov 15, 2024

Revolution Medicines executive sells shares worth $977,508 - Investing.com

Nov 15, 2024

Nov 15, 2024

Revolution Medicines' SWOT analysis: stock rises on cancer drug pipeline By Investing.com - Investing.com Australia

Nov 15, 2024

Nov 15, 2024

Revolution Medicines' SWOT analysis: stock rises on cancer drug pipeline - Investing.com India

Nov 15, 2024

Nov 13, 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Nov 13, 2024

Nov 11, 2024

Revolution Medicines (NASDAQ:RVMD) Reaches New 12-Month HighStill a Buy? - MarketBeat

Nov 11, 2024

Nov 11, 2024

HC Wainwright Issues Pessimistic Estimate for RVMD Earnings - MarketBeat

Nov 11, 2024

Nov 11, 2024

What is Wedbush's Forecast for RVMD FY2024 Earnings? - MarketBeat

Nov 11, 2024

Nov 09, 2024

Revolution Medicines' general counsel sells $360,000 in stock - Investing.com India

Nov 09, 2024

Nov 09, 2024

Revolution Medicines Stock Soars to All-Time High of $60.53 By Investing.com - Investing.com Canada

Nov 09, 2024

Nov 09, 2024

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight - Yahoo Finance

Nov 09, 2024

Nov 09, 2024

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com

Nov 09, 2024

Nov 08, 2024

Wellington Management Group LLP Reduces Stake in Revolution Medi - GuruFocus.com

Nov 08, 2024

Nov 08, 2024

Revolution Medicines' general counsel sells $360,000 in stock By Investing.com - Investing.com UK

Nov 08, 2024

Nov 08, 2024

Revolution Medicines Stock Soars to All-Time High of $60.53 - Investing.com

Nov 08, 2024

Nov 08, 2024

Earnings call: Revolution Medicines reports on RAS(ON) inhibitors progress By Investing.com - Investing.com Australia

Nov 08, 2024

Nov 07, 2024

Earnings call: Revolution Medicines reports on RAS(ON) inhibitors progress - Investing.com

Nov 07, 2024

Nov 07, 2024

HC Wainwright Issues Negative Outlook for RVMD Earnings - MarketBeat

Nov 07, 2024

Nov 07, 2024

JPMorgan Chase & Co. Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - MarketBeat

Nov 07, 2024

Nov 07, 2024

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus.com

Nov 07, 2024

Nov 07, 2024

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Nov 07, 2024

Nov 07, 2024

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Nov 07, 2024

Nov 07, 2024

Revolution Medicines Reports Q3 2024 Results and Progress - TipRanks

Nov 07, 2024

Nov 06, 2024

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress - The Manila Times

Nov 06, 2024

Nov 06, 2024

Revolution Medicines' SWOT analysis: cancer drug developer's stock potential By Investing.com - Investing.com Australia

Nov 06, 2024

Nov 05, 2024

Revolution Medicines CEO Mark A. Goldsmith sells $3.88 million in stock - Investing.com Canada

Nov 05, 2024

Nov 05, 2024

Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighWhat's Next? - MarketBeat

Nov 05, 2024

Nov 05, 2024

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com

Nov 05, 2024

Nov 05, 2024

Revolution Medicines to Participate in Upcoming Investor Conferences - The Manila Times

Nov 05, 2024

Nov 05, 2024

Revolution Medicines' SWOT analysis: cancer drug developer's stock potential - Investing.com India

Nov 05, 2024

Nov 05, 2024

Brokerage firm bumps Revolution Medicines stock PT on positive trial data - Investing.com Canada

Nov 05, 2024

Nov 04, 2024

(RVMD) Long Term Investment Analysis - Stock Traders Daily

Nov 04, 2024

Nov 01, 2024

Revolution Medicines (NASDAQ:RVMD) Given New $60.00 Price Target at Oppenheimer - Defense World

Nov 01, 2024

Oct 31, 2024

Revolution Medicines (RVMD) Set to Announce Earnings on Wednesday - MarketBeat

Oct 31, 2024

Oct 31, 2024

Allspring Global Investments Holdings LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Oct 31, 2024

Oct 30, 2024

Revolution Medicines stock hits 52-week high at $51.01 By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 30, 2024

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - The Manila Times

Oct 30, 2024

Oct 30, 2024

Revolution Medicines stock hits 52-week high at $51.01 - Investing.com

Oct 30, 2024

Oct 30, 2024

Raymond James & Associates Purchases 116,135 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Oct 30, 2024

Oct 29, 2024

China Universal Asset Management Co. Ltd. Purchases 12,744 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Oct 29, 2024

Oct 28, 2024

Revolution Medicines (NASDAQ:RVMD) PT Raised to $82.00 - MarketBeat

Oct 28, 2024

Oct 28, 2024

Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts - BioSpace

Oct 28, 2024

Oct 26, 2024

Revolution Medicines reports positive RMC-9805 study results - Investing.com India

Oct 26, 2024

Oct 25, 2024

Revolution Medicines reports positive RMC-9805 study results By Investing.com - Investing.com Australia

Oct 25, 2024